CD20-targeted therapies mainly involve monoclonal antibodies (mAbs) that bind specifically to the CD20 protein on the surface of B cells. The most well-known of these is Rituximab, which was the first CD20-targeting antibody approved by the FDA. Other mAbs, such as Ofatumumab and Obinutuzumab, have also been developed to improve efficacy and overcome resistance.
